Kamada makes management changes
This article was originally published in Scrip
Executive Summary
Kamada, a plasma-derived protein therapeutics company focused on orphan indications, has announced executive management changes intended to strengthen the company's leadership. Under the changes, David Tsur, co-founder and CEO, will become deputy executive chair of the board, a new position whereby he will maintain his strategic advisory role yet relinquish day-to-day management responsibilities. Leon Recanti will remain the chair of the board. Amir London, the company's senior vice-president of business development, will become CEO and Gil Efron, currently chief financial officer, will take on the added role of deputy CEO. The changes are expected to go into effect in July 2015.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.